Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.

Jhong-Ru Huang Chung-Wei Chou Heng-Sheng Chao

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Given that the ALK inhibitors are the treatment of choice for advanced lung cancer patients with ALK rearrangement. Our report demonstrated the potential feasibility of alectinib re-use in cases of severe druginduced ILD.

Keyphrases

interstitial lung disease
systemic sclerosis
rheumatoid arthritis
idiopathic pulmonary fibrosis
drug induced
early onset
advanced non small cell lung cancer
high glucose
disease activity
diabetic rats
ulcerative colitis
oxidative stress
risk assessment
human health
tyrosine kinase
smoking cessation